AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19833270 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% levobupivacaine
Number of subjects: 73
Study 16698413 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole treatment every 2 months for 12 months (total of 7 treatments)
Number of subjects: 2373
Study 16698413 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 2373
Study 16698413 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole treatment
Number of subjects: 2373
Study 15471004 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine
Number of subjects: 107
Study 15471004 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 107
Study 15471004 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 107
Study 11471776 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 18
Study 9489589 — intervention group
Group type: COMPARATOR
Intervention: Marimastat 25, 50, 100, 200, 400, and 800 mg single doses
Number of subjects: 31
Study 9489589 — intervention group
Group type: COMPARATOR
Intervention: Marimastat 50, 100, and 200 mg twice daily for 6.5 days
Number of subjects: 31
Study 7817726 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperemesis gravidarum patients
Number of subjects: 39
Study 7817726 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (23 subjects of comparable gestational age)
Number of subjects: 39
Study 3398127 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative course of oral antibiotics (group 2)
Number of subjects: 138
Study 3398127 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic (controls, group 1)
Number of subjects: 138
Study 3398127 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence
Number of subjects: 138
Study 3398127 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic infection
Number of subjects: 138
Study 31680604 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3/Omega-6 fatty acids
Number of subjects: 40
Study 29190847 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicated preterm birth (IPTB)
Number of subjects: 9867
Study 29190847 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous preterm birth (SPTB)
Number of subjects: 9867
Study 26968359 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionation (19 fractions of 3.4 Gy in 6.5 weeks)
Number of subjects: 820
Study 26968359 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation (39 fractions of 2 Gy in 8 weeks)
Number of subjects: 820
Study 25896635 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG at 0.5 g/kg per week
Number of subjects: 23
Study 25896635 — intervention group
Group type: COMPARATOR
Intervention: IVIG at 1 g/kg per week
Number of subjects: 23
Study 23605883 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice daily
Number of subjects: 126
Study 23605883 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab 5 mg/kg every 2 weeks
Number of subjects: 126
Study 23605883 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice daily plus bevacizumab 2 mg/kg every 2 weeks
Number of subjects: 126
Study 20529983 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg hyperbaric 2% prilocaine
Number of subjects: 90
Study 20529983 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg hyperbaric 2% prilocaine
Number of subjects: 90
Study 20529983 — intervention group
Group type: COMPARATOR
Intervention: 60 mg plain 2% prilocaine
Number of subjects: 90
Study 18379200 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 50
Study 18379200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 18379200 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Montelukast and Placebo)
Number of subjects: 50
Study 16603098 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole (antimycotic agent)
Number of subjects: 126
Study 16603098 — intervention group
Group type: COMPARATOR
Intervention: Yeast infected but not treated patients
Number of subjects: 126
Study 16603098 — intervention group
Group type: COMPARATOR
Intervention: Yeast-free controls
Number of subjects: 126
Study 12909511 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of autocrosslinked hyaluronic acid (HA) gel (group A)
Number of subjects: 36
Study 12909511 — intervention group
Group type: COMPARATOR
Intervention: No application of autocrosslinked hyaluronic acid (HA) gel (group B)
Number of subjects: 36
Study 9520227 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg q.i.d.)
Number of subjects: 184
Study 9520227 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg q.i.d.) plus Codeine (40 mg q.i.d.)
Number of subjects: 184
Study 9520227 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg q.i.d.) plus Imipramine (10 or 25 mg t.i.d.)
Number of subjects: 184
Study 9520227 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Diclofenac (50 mg q.i.d.)
Number of subjects: 184
Study 7924321 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestogen-only contraceptives (pill, DMPA, NET-EN, NORPLANT implants)
Number of subjects: 2466
Study 7924321 — intervention group
Group type: COMPARATOR
Intervention: Non-hormonal methods (IUD, barrier methods, sterilization)
Number of subjects: 2466
Study 2622580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 600 mg/day for 3 days
Number of subjects: 45
Study 2622580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 300 mg/day for 3 days
Number of subjects: 45
Study 2622580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 600 mg/day for 5 days
Number of subjects: 45
Study 1091029 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg of adenine infused intravenously over one hour
Number of subjects: 8
Study 1091029 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg of adenine infused intravenously over one hour
Number of subjects: 8
Study 1091029 — intervention group
Group type: COMPARATOR
Intervention: No adenine (control group)
Number of subjects: 8
Study 31773200 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month exercise programme for reducing abdominal fat (PRAF)
Number of subjects: 70
Study 31773200 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 30024294 — intervention group
Group type: EXPERIMENTAL
Intervention: High loneliness induction
Number of subjects: 97
Study 30024294 — intervention group
Group type: COMPARATOR
Intervention: Low loneliness induction
Number of subjects: 97
Study 28606267 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate eye drop (Group B)
Number of subjects: 102
Study 28606267 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid‐containing carbomer gel (Group C)
Number of subjects: 102
Study 28606267 — intervention group
Group type: COMPARATOR
Intervention: Conventional antibiotics (Group A)
Number of subjects: 102
Study 28606267 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate eye drop (Group B) and Lipid‐containing carbomer gel (Group C)
Number of subjects: 102
Study 23811112 — intervention group
Group type: EXPERIMENTAL
Intervention: Danoprevir 300 mg every 8 hours
Number of subjects: 237
Study 23811112 — intervention group
Group type: EXPERIMENTAL
Intervention: Danoprevir 600 mg every 12 hours
Number of subjects: 237
Study 23811112 — intervention group
Group type: EXPERIMENTAL
Intervention: Danoprevir 900 mg every 12 hours
Number of subjects: 237
Study 23811112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 20643862 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin plus pegylated liposomal doxorubicin (PLD)
Number of subjects: 214
Study 20643862 — intervention group
Group type: COMPARATOR
Intervention: PLD alone
Number of subjects: 214
Study 19586701 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ-IO
Number of subjects: 29
Study 19586701 — intervention group
Group type: COMPARATOR
Intervention: BIG
Number of subjects: 29
Study 17432638 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-needling combined with medication
Number of subjects: 120
Study 17432638 — intervention group
Group type: COMPARATOR
Intervention: Medication (control group)
Number of subjects: 120
Study 15361698 — intervention group
Group type: EXPERIMENTAL
Intervention: End-stage renal disease (ESRD)
Number of subjects: 47
Study 15361698 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 11401920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytobrush samples (n = 120)
Number of subjects: 120
Study 11401920 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash samples (n = 40)
Number of subjects: 120
Study 11401920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytobrush samples (n = 28) in phase 2
Number of subjects: 120
Study 11401920 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash samples (n = 25) in phase 2
Number of subjects: 120
Study 11401920 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash extracts
Number of subjects: 120
Study 11401920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytobrush extracts
Number of subjects: 120
Study 11401920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytobrush and mouthwash phenol‐chloroform extracts
Number of subjects: 120
Study 11401920 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOH extracted DNA from cytobrush samples
Number of subjects: 120
Study 11401920 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash or cytobrush samples
Number of subjects: 120
Study 11401920 — intervention group
Group type: EXPERIMENTAL
Intervention: Single mouthwash sample
Number of subjects: 120
Study 10069757 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low-molecular-weight heparin (LMWH), tinzaparin sodium, once-daily dose.
Number of subjects: 200
Study 10069757 — intervention group
Group type: COMPARATOR
Intervention: Intravenous heparin therapy, initial continuous intravenous infusion followed by 3 months of warfarin therapy.
Number of subjects: 200
Study 7992418 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision, curettage and primary suture under antibiotic cover
Number of subjects: 17
Study 7992418 — intervention group
Group type: COMPARATOR
Intervention: Conventional, 'open' treatment
Number of subjects: 17
Study 1969068 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination (test group)
Number of subjects: 114
Study 1969068 — intervention group
Group type: COMPARATOR
Intervention: Conventional perioperative antibiotic prophylaxis (controls)
Number of subjects: 114
Study 665 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate
Number of subjects: 40
Study 665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31852712 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (1500 mg), thiamine (100 mg), hydrocortisone (50 mg) every 6 hours for 4 days
Number of subjects: 0
Study 31852712 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 6 hours for 4 days
Number of subjects: 0
Study 31852712 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid, corticosteroids and thiamine
Number of subjects: 0
Study 31852712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28549298 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-night dinner at 2100h (D21)
Number of subjects: 16
Study 28549298 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided dinner (vegetable and rice at 1800h and main dish at 2100h)
Number of subjects: 16
Study 28549298 — intervention group
Group type: COMPARATOR
Intervention: Dinner at 1800h (D18)
Number of subjects: 16
Study 26036543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 67
Study 26036543 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (Tac)
Number of subjects: 67
Study 24165049 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve adjustment (group B)
Number of subjects: 102
Study 21543951 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-focus schema therapy
Number of subjects: 105
Study 21543951 — intervention group
Group type: COMPARATOR
Intervention: Individual drug counseling
Number of subjects: 105
Study 19428879 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-valent pneumococcal conjugate vaccine (11PCV)
Number of subjects: 1111
Study 19428879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1111
Study 16457000 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up infected group (FU-I)
Number of subjects: 195
Study 16457000 — intervention group
Group type: COMPARATOR
Intervention: Follow-up noninfected group (FU-NI)
Number of subjects: 195
Study 16457000 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 195
Study 16510656 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral assessment using Conners' Parent Rating Scale
Number of subjects: 274
Study 16510656 — intervention group
Group type: EXPERIMENTAL
Intervention: Wechsler Intelligence Scale for Children-III
Number of subjects: 274
Study 16510656 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 lymphocyte count correlation
Number of subjects: 274
Study 16510656 — intervention group
Group type: EXPERIMENTAL
Intervention: Age correlation with anxiety problems
Number of subjects: 274
Study 16510656 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging correlation
Number of subjects: 274
Study 12732767 — intervention group
Group type: EXPERIMENTAL
Intervention: Early second-look laparoscopy (SLL) with adhesiolysis in 46 women (group 1)
Number of subjects: 90
Study 12732767 — intervention group
Group type: COMPARATOR
Intervention: No second-look laparoscopy in 44 women (group 2)
Number of subjects: 90
Study 10361108 — intervention group
Group type: COMPARATOR
Intervention: TAD (standard-dose cytarabine with daunorubicin and 6-thioguanine)
Number of subjects: 725
Study 10361108 — intervention group
Group type: EXPERIMENTAL
Intervention: TAD-HAM (high-dose cytarabine with mitoxantrone)
Number of subjects: 725
Study 10361108 — intervention group
Group type: EXPERIMENTAL
Intervention: TAD-HAM (high-dose cytarabine with mitoxantrone) in poor prognosis subgroup
Number of subjects: 725
Study 10361108 — intervention group
Group type: COMPARATOR
Intervention: TAD (standard-dose cytarabine with daunorubicin and 6-thioguanine) in poor prognosis subgroup
Number of subjects: 725
Study 7676504 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion formulation of CsA, 400 mg oral dose
Number of subjects: 11
Study 7676504 — intervention group
Group type: COMPARATOR
Intervention: Currently marketed formulation of CsA, 400 mg oral dose
Number of subjects: 11
Study 2155476 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs) including acetylsalicylic acid, carprofen, diclofenac, indomethacin, naproxen, proquazone, timegadine, tolfenamic acid, paracetamol
Number of subjects: 53
Study 2155476 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 53
Study 112265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 14
Study 112265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31719078 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) route - 8 infusions over 4 days, then again for 4 days in week 4 (total of 240 g of stool)
Number of subjects: 30
Study 31719078 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopic infusion followed by seven weekly enemas (total of 360 g of stool)
Number of subjects: 30
Study 28263734 — intervention group
Group type: COMPARATOR
Intervention: IOL Master 500
Number of subjects: 79
Study 28263734 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentacam AXL
Number of subjects: 79
Study 28263734 — intervention group
Group type: EXPERIMENTAL
Intervention: All devices
Number of subjects: 79
Study 26209856 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intraoperative dose of dexamethasone
Number of subjects: 734
Study 26209856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 734
Study 23537954 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG SXscore
Number of subjects: 115
Study 23537954 — intervention group
Group type: COMPARATOR
Intervention: Low CABG SXscore group
Number of subjects: 115
Study 22132755 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion treatment at 4 acupuncture points, ST23 and ST27, bilaterally, 3 times per week for four weeks.
Number of subjects: 26
Study 22132755 — intervention group
Group type: COMPARATOR
Intervention: Sham moxibustion treatment at 4 acupuncture points, ST23 and ST27, bilaterally, 3 times per week for four weeks.
Number of subjects: 26
Study 22132755 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion treatment
Number of subjects: 26
Study 19421690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention hospital
Number of subjects: 641
Study 19421690 — intervention group
Group type: COMPARATOR
Intervention: Control hospital
Number of subjects: 641
Study 17087245 — intervention group
Group type: EXPERIMENTAL
Intervention: Clexane, 40 mg, administered 12 hours before and within 7-18 days after surgery
Number of subjects: 80
Study 17087245 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific prevention of thrombotic events
Number of subjects: 80
Study 15021224 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Peripheral Iridotomy (LPI)
Number of subjects: 0
Study 15021224 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Peripheral Iridoplasty
Number of subjects: 0
Study 15021224 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Lens Extraction
Number of subjects: 0
Study 15021224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular Hypertension (OH) treatment
Number of subjects: 0
Study 15021224 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk OH and Primary Open Angle Glaucoma (POAG) treatment
Number of subjects: 0
Study 15021224 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost and Brimonidine
Number of subjects: 0
Study 15021224 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy combined with Blumenthal technique
Number of subjects: 0
Study 11182670 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented surgery (group A)
Number of subjects: 43
Study 11182670 — intervention group
Group type: COMPARATOR
Intervention: Prism adaptation (group P)
Number of subjects: 43
Study 9286520 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing 0.25 mg F as NaF for 5, 10, 15, 20, 30, or 45 minutes
Number of subjects: 10
Study 9286520 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 10
Study 9286520 — intervention group
Group type: COMPARATOR
Intervention: Non-chewing side
Number of subjects: 10
Study 12959292 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified metered‐dose actuator device (MA)
Number of subjects: 10
Study 12959292 — intervention group
Group type: COMPARATOR
Intervention: Standard metered‐dose inhaler (MDI)
Number of subjects: 10
Study 3526720 — intervention group
Group type: EXPERIMENTAL
Intervention: Eleutherococcus extract
Number of subjects: 0
Study 31096498 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral carbohydrate solution 710 mL the night before and 355 mL 2 hours prior to operation
Number of subjects: 73
Study 31096498 — intervention group
Group type: COMPARATOR
Intervention: Fasting for 10 hours prior to operation
Number of subjects: 73
Study 28603100 — intervention group
Group type: EXPERIMENTAL
Intervention: Total closure of pancreatic section for end‐to‐side pancreaticojejunostomy (Group A)
Number of subjects: 123
Study 28603100 — intervention group
Group type: COMPARATOR
Intervention: Conventional pancreaticojejunostomy (Group B)
Number of subjects: 123
Study 25921843 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1500 mg/day)
Number of subjects: 38
Study 25921843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 25921843 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 38
Study 23032410 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with ritonavir-boosted lopinavir (LPV/r)
Number of subjects: 49
Study 23032410 — intervention group
Group type: COMPARATOR
Intervention: Continued therapy
Number of subjects: 49
Study 23032410 — intervention group
Group type: COMPARATOR
Intervention: Alzheimer dementia
Number of subjects: 49
Study 22046723 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician's gaze
Number of subjects: 110
Study 22046723 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-based response
Number of subjects: 110
Study 19067075 — intervention group
Group type: EXPERIMENTAL
Intervention: DJBS
Number of subjects: 39
Study 19067075 — intervention group
Group type: COMPARATOR
Intervention: Low fat diet control
Number of subjects: 39
Study 16957558 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine 100 mg/kg (study 1)
Number of subjects: 43
Study 16957558 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine 200 mg/kg (study 2)
Number of subjects: 43
Study 16957558 — intervention group
Group type: COMPARATOR
Intervention: Placebo (study 1 and study 2)
Number of subjects: 43
Study 15354036 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion (20% in saline; carbohydrate (CHO) at a rate of 1 g x min(‐1))
Number of subjects: 6
Study 15354036 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% saline; placebo (PLA))
Number of subjects: 6
Study 12573179 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Scheduled Gradual Reduction (CSGR)
Number of subjects: 93
Study 12573179 — intervention group
Group type: COMPARATOR
Intervention: Manual-based Selective Elimination Reduction (SER)
Number of subjects: 93
Study 12573179 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CSGR and SER)
Number of subjects: 93
Study 12573179 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with a current desire for smoking cessation
Number of subjects: 93
Study 9686797 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic harvesting technique (EHT)
Number of subjects: 60
Study 9686797 — intervention group
Group type: COMPARATOR
Intervention: Open harvesting technique (OHT)
Number of subjects: 60
Study 7978956 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin‐releasing hormone agonist (GnRHa) in depot formulation (Zoladex) with transdermal 17‐beta‐estradiol and oral progestin
Number of subjects: 40
Study 7978956 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40